GSK’s joint venture HIV drug wins approval in Europe

A ViiV Healthcare HIV drug has received regulatory approval from the European Commission.

GSK (NYSE: GSK) and Pfizer (NYSE: PFE) formed ViiV as a joint venture.

The treatment was approved for use in HIV infected adults and adolescents above 12 years of age, GSK said in London.

The drug is called Tivicay.

London-based ViiV maintains its U.S. operations on GSK’s campus in Research Triangle Park.

“HIV treatment is not a question of ‘one-size fits all’ – especially now that treatment is something that patients will live with for many years,” said Dr John Pottage, Chief Medical Officer of ViiV Healthcare. “We continue to find measurable clinical differences among the treatments now available for use in combination therapy to combat HIV. Using the clinical data for Tivicay, doctors and people living with HIV can fully consider the effectiveness against the virus and the side effect profile that Tivicay may bring.”

The full GSK announcement including trial result details can be read online.

[GSK ARCHIVE: Check out more than a decade of GSK stories as reported in WRALTechWire.]